

Amendments to the Claims

This listing of claims replaces all prior versions, and listings, of claims in the application.

Claims 1-19 (canceled)

20. (new) A monoclonal antibody comprising a variant of a parent human Fc region, wherein the amino acid sequence of the parent human Fc region is selected from the group consisting of SEQ ID NOs: 1, 2, 3 and 4, and wherein the variant consists of a parent human Fc region substituted at one of the following positions with the amino acid indicated: position 251 with a phenylalanine, position 256 with a methionine, 256 with a proline, position 268 with a glutamic acid, position 268 with an aspartic acid, position 280 with a lysine, position 332 with an arginine, position 378 with an aspartic acid or position 440 with a tyrosine.
21. (new) A monoclonal antibody comprising a variant of a parent human Fc region, wherein the amino acid sequence of the parent human Fc region is selected from the group consisting of SEQ ID NOs: 1, 2, 3 and 4, and wherein the variant consists of a parent human Fc region substituted at position 247 with an amino acid selected from the group consisting of leucine and isoleucine.
22. (new) The monoclonal antibody of claim 21 wherein the variant consists of a parent human Fc region substituted at position 247 with an isoleucine.
23. (new) The monoclonal antibody of claim 22, wherein the antibody specifically binds human CD20.
24. (new) A composition comprising a therapeutically effective amount of the antibody of claim 23.
25. (new) A monoclonal antibody comprising a variant of a parent human Fc region, wherein the amino acid sequence of the parent human Fc region is selected from the group consisting of SEQ ID NOs: 1, 2, 3 and 4, and wherein the variant consists of a 332K amino acid substitution.